19181-77-2Relevant articles and documents
QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
-
Page/Page column 108-109, (2021/06/22)
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
QUINAZOLINE CARBOXAMIDE AZETIDINES
-
Page/Page column 25, (2012/06/15)
The invention provides novel quinazoline carboxamide azetidine compounds according to Formula (I) and use for the treatment of hyperproliferative diseases, such as cancer.
RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 86, (2011/04/14)
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.